title: Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.
abstract: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase (MAPK) have been used extensively in vitro and in vivo to investigate the role of p38 in physiological processes. As with other pharmacological inhibitors, non-specific targets of the p38 inhibitors have been reported. We have found that the protein kinase receptor interacting protein-2 (RIP2) is another target for the family of p38 inhibitors. The autophosphorylation of RIP2 was inhibited in vitro by the p38 inhibitors SB220025, SB203580 and PD169316 at concentrations comparable to those used to inhibit p38. We also identified two new in vitro substrates for RIP2, myelin basic protein and histone H3 with apparent Km values of 2.1 microM and 0.65 microM, respectively. The ability of RIP2 to phosphorylate these two substrates was sensitive to the p38 inhibitors as well. As was shown for p38alpha, a conserved threonine in the kinase domain of RIP2 is required for sensitivity to the inhibitors, indicating that the mechanism of inhibition of RIP2 is similar to that of p38. These results demonstrate that the pyridinyl imidazole inhibitors block RIP2 as well as p38 kinase activity.
authors.affiliation: Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO, USA.
authors.forename: Gretchen M
authors.initials: GM
authors.lastname: Argast
authors.forename: Nelson
authors.initials: N
authors.lastname: Fausto
authors.forename: Jean S
authors.initials: JS
authors.lastname: Campbell
mesh_terms: D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017434:Protein Structure, Tertiary / Q000502:physiology; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D013379:Substrate Specificity; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D007093:Imidazoles; D017346:Protein Serine-Threonine Kinases; C506253:RIPK2 protein, human; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D048051:p38 Mitogen-Activated Protein Kinases
references.citation: J Biol Chem. 2000 Mar 10;275(10 ):7395-402
references.pmid: 10702313
references.citation: FEBS Lett. 1999 Feb 5;444(1):71-4
references.pmid: 10037150
references.citation: EMBO J. 1996 Apr 15;15(8):1914-23
references.pmid: 8617238
references.citation: Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):674-8
references.pmid: 7904757
references.citation: J Biol Chem. 1998 Jul 3;273(27):16968-75
references.pmid: 9642260
references.citation: J Biol Chem. 2002 Aug 9;277(32):28364-7
references.pmid: 12077112
references.citation: FEBS Lett. 1999 May 21;451(2):191-6
references.pmid: 10371163
references.citation: Biochemistry. 1998 Nov 24;37(47):16573-81
references.pmid: 9843424
references.citation: Biochemistry. 1997 Aug 26;36(34):10422-7
references.pmid: 9265622
references.citation: Oncogene. 1999 Mar 25;18(12 ):2047-54
references.pmid: 10321729
references.citation: EMBO Rep. 2002 Dec;3(12):1201-8
references.pmid: 12446564
references.citation: Biochem J. 2000 Oct 1;351(Pt 1):95-105
references.pmid: 10998351
references.citation: J Biol Chem. 1999 Nov 19;274(47):33684-90
references.pmid: 10559258
references.citation: Chem Biol. 1997 Jun;4(6):423-31
references.pmid: 9224565
references.citation: Cell. 2000 Sep 29;103(1):99-111
references.pmid: 11051551
references.citation: Structure. 1998 Sep 15;6(9):1117-28
references.pmid: 9753691
references.citation: Mol Cell Biol. 2003 Jan;23 (2):425-36
references.pmid: 12509443
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15434-9
references.pmid: 14668439
references.citation: J Biol Chem. 1998 May 15;273(20):12296-300
references.pmid: 9575181
references.citation: J Clin Immunol. 2001 Jul;21(4):253-7
references.pmid: 11506194
references.citation: FEBS Lett. 1998 Apr 10;426(1):93-6
references.pmid: 9598985
references.citation: Nature. 1994 Dec 22-29;372(6508):739-46
references.pmid: 7997261
references.citation: J Biol Chem. 1998 Jun 19;273(25):15605-10
references.pmid: 9624152
references.citation: Nature. 2002 Mar 14;416(6877):194-9
references.pmid: 11894098
references.citation: Chem Biol. 1998 Jun;5(6):321-8
references.pmid: 9653550
references.citation: J Biol Chem. 2003 Aug 22;278(34):31941-9
references.pmid: 12775719
references.citation: Nature. 2002 Mar 14;416(6877):190-4
references.pmid: 11894097
references.citation: Curr Biol. 1998 Jul 16;8(15):885-8
references.pmid: 9705938
references.citation: J Biol Chem. 1998 Oct 30;273(44):28766-72
references.pmid: 9786874
references.citation: J Biol Chem. 1997 May 2;272(18):12116-21
references.pmid: 9115281
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):687-92
references.pmid: 9454815
references.citation: Bioorg Med Chem. 1997 Jan;5(1):49-64
references.pmid: 9043657